CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

70 citing papers in PubMed, 102 citations in OpenAlex.

1. Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.Current HIV/AIDS reports · 2025
   Review
2. Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection.Biomarker research · 2024
   Article
3. Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery.Gene therapy · 2024
   Article
4. AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.Biomaterials · 2023
   Article
5. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4Cell host & microbe · 2023
   Article
6. Beyond the Syndemic of Opioid Use Disorders and HIV: The Impact of Opioids on Viral Reservoirs.Viruses · 2023
   Review
7. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods.Cell reports methods · 2023
   Article
8. Antigen specificities of HIV-infected cells: A role in infection and persistence?Journal of virus eradication · 2023
   Review
9. Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection.mBio · 2022
   Article
10. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.Viruses · 2022
    Article
11. Defective HIV-1 genomes and their potential impact on HIV pathogenesis.Retrovirology · 2022
    Review
12. Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.Current HIV/AIDS reports · 2022
    Review
13. Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response.eLife · 2022
    Article
14. CXCR3 Expression Pattern on CD4+ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue.Pathogens (Basel, Switzerland) · 2022
    Article
15. Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.Frontiers in immunology · 2022
    Review
16. Cure and Long-Term Remission Strategies.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
17. Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.mBio · 2021
    Article
18. Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising HumanLife (Basel, Switzerland) · 2021
    Article
19. Flow-FISH as a Tool for Studying Bacteria, Fungi and Viruses.Biotech (Basel (Switzerland)) · 2021
    Review
20. The Contributions of Clinical Pharmacology to HIV Cure Research.Clinical pharmacology and therapeutics · 2021
    Review

10 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

34 authors at 12 institutions in 3 countries.

Funding

Abstract

Indexed as